No profile data available.
XTL Biopharmaceuticals Ltd. (XTLB) is a technology company in the data analytics platforms industry, based in Herzliya, Israel, with about 4 full-time employees.
It reported revenue of $451,000 for fiscal year 2024, and net income of -$1.03 million. Its market capitalization was $4.87 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
XTL Biopharmaceuticals reported $451,000 in revenue for fiscal year 2024.
$4.87 million as of October 9, 2026.
Listed companies of a similar size in the same industry (data analytics platforms) include Veritone, Inc. (VERI), Universal New Energy Holding Group, Inc. (UNEH), Nvni Group Limited (NVNI).